Anastasia A. Kozyreva

Anastasia A. Kozyreva

Auto-generated profile, based on publicly available information

Anastasia A. Kozyreva

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
AKA.A. Kozyreva
A.A. Kozyreva
RBR.TS. Bembeeva
R.TS. Bembeeva
EDE.S. Druzhinina
E.S. Druzhinina
NZNikolay Zavadenko
Nikolay Zavadenko
Guillain—Barré syndrome (GBS) is an immune-mediated disease of the peripheral nervous system that can occur in both children and adults. The classic presentation of GBS is characterized by progressive symmetrical, ascending muscle weakness. Patients with GBS require meticulous monitoring due to the risk of bulbar syndrome, respiratory failure and autonomic dysfunction, which can be life-threatening. Early diagnosis and timely prescription of pathogenetic therapy for GBS are particularly important, especially in young children. Meanwhile, the spectrum of disorders covered by GBS has expanded significantly; its eponym is now designate any variant of acute dysimmune polyneuropathy, and its atypical forms pose a serious diagnostic problem for clinicians. This review article provides an analysis of the data available in the medical literature on GBS in children and discusses the tactics for diagnosing and managing patients with GBS, taking into account the Russian and European clinical recommendations.

30 September 2021 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
УАУмида Маликовна Азизова
Умида Маликовна Азизова
RBRaisa Ts. Bembeeva
Raisa Ts. Bembeeva
AKAnastasia A. Kozyreva
Anastasia A. Kozyreva
NZNikolay Zavadenko
Nikolay Zavadenko
Autoimmune diseases of the central nervous system (CNS) are one of the most socially and economically significant problems of neurology. Despite the identification of new nosological forms of autoimmune encephalitis, the creation of diagnostic panels for the verification of autoantibodies in biological fluids, and the use of highly effective pathogenetic therapy, the number of diagnostic errors remains high, which poses a threat to the patient’s life and a high risk of developing severe complications. Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis) is autoimmune encephalitis caused by the presence of antibodies (Ab) to the NR1 subunit of NMDA-receptors (NMDAR) characterized by the development of severe mental and neurological deficits in a previously healthy person. This article summarizes the recent literature on anti-NMDAR encephalitis. The literature search was carried out using the Scopus, Web of Science, Pubmed, CyberLeninka databases. The review presents the facts of the history of the study of the disease, epidemiological data, modern ideas about the pathogenetic mechanisms of the development of the disease, the spectrum of clinical manifestations and various forms of the course of the disease. The diagnostic criteria and research methods used to confirm the diagnosis are described, approaches to the treatment of anti-NMDAR encephalitis are outlined. Anti-NMDAR encephalitis is clinically manifested by a combination of mental disorders, epileptic seizures, speech and extrapyramidal disorders, and disturbances in the rhythm of sleep and wakefulness. The disease occurs at any age. The development of the disease can be associated with such immunological triggers as oncological process and herpetic encephalitis, or be idiopathic in nature. There are features of the course of the clinical picture depending on the age of the patient, paraneoplastic or postherpetic aetiology of the disease. The diagnostic algorithm, along with neuroimaging, determination of specific antibodies, electroencephalography, should also include the search for an oncological process. The recovery of patients can take from several months to years. In some cases, persistent neurological deficits develop. Predictors of a favourable outcome include early initiation and use of combination therapy, detection and removal of neoplasms, a low titer of anti-NMDAR antibodies, and age of patients over 12 years of age. In up to 25% of cases, a relapsing course of the disease is possible, and therefore requires long-term monitoring of these patients.

11 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
AKA.A. Kozyreva
A.A. Kozyreva
RBR.TS. Bembeeva
R.TS. Bembeeva
EDE.S. Druzhinina
E.S. Druzhinina
NZNikolay Zavadenko
Nikolay Zavadenko
LKL.M. Kolpakchi
L.M. Kolpakchi
SPS.V. Pilia
S.V. Pilia
OBJECTIVE Analysis of demographic, clinical, laboratory, electrophysiological and neuroimaging data and pathogenetic therapy of pediatric patients with chronic inflammatory demyelinating polyneuropathy (CIDP). MATERIAL AND METHODS Patients (n=30) were observed in a separate structural unit of the Russian Children’s Clinical Hospital of the Russian National Research Medical University named after. N.I. Pirogova Ministry of Health of the Russian Federation in the period from 2006 to 2023. The examination was carried out in accordance with the recommendations of the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society on the Management of CIDP (2021). All patients received immunotherapy, including intravenous immunoglobulin (IVIG) (n=1), IVIG and glucocorticosteroids (GCS) (n=17, 56.7%), IVIG+GCS+plasmapheresis (n=12, 40.0%). Alternative therapy included cyclophosphamide (n=1), cyclophosphamide followed by mycophenolate mofetil (n=1), rituximab (n=2, 6.6%), azathioprine (n=3), mycophenolate mofetil (n=2, 6.6%). RESULTS In all patients, there was a significant difference between scores on the MRCss and INCAT functional scales before and after treatment. At the moment, 11/30 (36.6%) patients are in clinical remission and are not receiving pathogenetic therapy. The median duration of remission is 48 months (30—84). The longest remission (84 months) was observed in a patient with the onset of CIDP at the age of 1 year 7 months. CONCLUSION Early diagnosis of CIDP is important, since the disease is potentially curable; early administration of pathogenetic therapy provides a long-term favorable prognosis.

26 March 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EDE.S. Druzhinina
E.S. Druzhinina
AKA.A. Kozyreva
A.A. Kozyreva
RBR.T. Bembeeva
R.T. Bembeeva
AKA.S. Kozlovsky
A.S. Kozlovsky
VSV.E. Sokolova
V.E. Sokolova
OTO.A. Tikhonova
O.A. Tikhonova
N-Hexane is a solvent widely used in manufacturing as a cleaner, degreaser and component of rubber cement. Chronic exposure to n-hexane either through contact with unprotected skin or inhalation can lead to the development of clinical symptoms and electrophysiological changes similar to those of inflammatory demyelinating polyneuropathy which requires careful differential diagnosis. This article presents three cases of severe predominantly motor polyneuropathy with demyelinating features in 15- and 16-year-old adolescents. The results of laboratory tests were within normal limits; electroneuromyography revealed symmetrical involvement of sensory and motor fibers of the nerves of the legs and arms with a decrease in the speed of propagation of excitation and conduction blocks. Sural nerve biopsy revealed intraneural and perineural swelling without any signs of inflammation or fibrosis confirming the genesis of the neuropathy. Despite a relatively favorable prognosis there is no specific therapy for hexane poisoning and the recovery period can last up to several years.

31 January 2025 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
АКАнастасия Андреевна Козырева
Анастасия Андреевна Козырева
РБРаиса Цеденкаевна Бембеева
Раиса Цеденкаевна Бембеева
ЕДЕвгения Сергеевна Дружинина
Евгения Сергеевна Дружинина
ASArmen K. Shakaryan
Armen K. Shakaryan
ГГГалина Дмитриевна Гусева
Галина Дмитриевна Гусева
NZNikolay Zavadenko
Nikolay Zavadenko
Introduction. In 2025, we will commemorate the 100th anniversary of the first pediatric case of Guillain–Barré Syndrome (GBS), initially documented by M. Monnier-Vinard. This significant milestone invites a reevaluation of our contemporary understanding of GBS in children. While the original description of GBS was thorough, the categorization has expanded over time to include a wider array of conditions, resulting in the term applied to various acute demyelinating polyneuropathies. The atypical forms of GBS present notable diagnostic challenges for healthcare providers. Objective. To analyze the demographic and clinical characteristics, treatment methods, and prognosis of GBS in children in Russia. Materials and methods. The study included fifty 6 months – 15 years patients with typical and atypical forms of Guillain-Barré syndrome (GBS). Neurological status was assessed using the Medical Research Council sum score and the Hughes disability scale. Additionally, data from cerebrospinal fluid analysis, nerve conduction study, magnetic resonance imaging of the spine, and peripheral nerves ultrasound was evaluated. Results. The classic ascending subtype of GBS was diagnosed in 30 (60%) patients, while atypical manifestations were observed in 17 (34%). Three (6%) patients had an overlap syndrome: GBS with acute myelitis. The median age of the patients was 7 [5.0; 11.0] years. Two peaks of GBS incidence associated with respiratory and gastrointestinal infections were identified. The most common initial symptoms were pain (80%), weakness in the legs (64%), and difficulty walking (54%). All 26 (100%) GBS patients were followed for 12 months from the onset of the disease regained the ability to walk. Conclusion. Both typical and atypical forms of GBS can occur in children. Overlap syndrome (GBS with acute myelitis) is a rare complication following COVID-19 and may go undiagnosed. With appropriate therapy the prognosis for both typical and atypical forms of GBS is generally favourable.

10 December 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
RBR.TS. Bembeyeva
R.TS. Bembeyeva
EUE.L. Usacheva
E.L. Usacheva
SPS.V. Piliya
S.V. Piliya
EIE.S. Ilyina
E.S. Ilyina
ASA.K. Shakaryan
A.K. Shakaryan
IFI.D. Fedonyuk
I.D. Fedonyuk
Subacute sclerosing panencephalitis (SSPE) is a rare complication caused by persistent measles infection and characterized by a decline in cognitive functions and severe motor impairments. Since SSPE is considered a potentially fatal complication of acute measles infection and is typically develops in young individuals especially those infected prior to the age of two years old, special attention must be paid to the implementation of vaccination programs that can prevent severe disease. Thus, the purpose of this research was to present the demographic and clinical characteristics of pediatric patients with SSPE in order to enhance its early diagnosis and to raise the pediatricians' awareness of this serious measles complication. In this series of case reports Authors represent the clinical picture, laboratory and instrumental data of six children with SSPE admitted at the Russian Children's Clinical Hospital with the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow, Russia) in Aug. 2022-Aug. 2024. Authors have conducted an analysis of complaints, clinical symptoms, laboratory, neurophysiological and neuroimaging data of 6 patients with SSPE. All patients have undergone cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI) of the brain and video EEG monitoring during both wakefulness and sleep at the time of diagnosis. Currently, there is no specific treatment for SSPE that would either lead to symptom regression or prevent the related disability. Therefore, vaccination remains the only effective means for the SSPE prevention.